Thanks HD Re the FYI ....the payment of any carried forward amount is subject to...etc I'm currently caffeine deprived so could you provide an easy answer Does this allow AMRN to pay as little at 10% of revenues and push remaining payments out to 2017 OR is this a way for Pharmakon to force them to play catch up to the agreed payment schedule ...if they can ramp sales....?
Going by your other excellent post DSMB can unblind if separation ( between the arms ) is sufficient ..especially if over 500 events have occurred....so if Pharmakon can NOT force AMRN to deplete its cash on hand ( by making $10m a qt payments in 2015 )...it makes AMRN look like a good spec buy.
Whats your take on the payments due Pharmakon ...if sales revenues are minimal going forward can Pharmakon force payment of the Qtly's or are the stuck with only 10% of revenue with the rest deferred.
News 
Market Data 
Discover 
AI
